The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

IMW 2019 | Multiple myeloma MRD assessment

Name: Multiple myeloma MRD assessment
Uploaded: 2019-09-14T00:00:00.000Z
Duration: 2 min 55 s
Description: Prof Fengyan Jin of Jilin University, Jilin, China, outlines the issues with current criteria regarding (measurable residual disease) MRD testing within clinical trials, namely the depth of MRD sensitivity, which cannot always be reached, and the suggested duration of MRD. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Fengyan Jin • 14 Sep 2019

IMW 2019

Multiple Myeloma

Prof Fengyan Jin of Jilin University, Jilin, China, outlines the issues with current criteria regarding (measurable residual disease) MRD testing within clinical trials, namely the depth of MRD sensitivity, which cannot always be reached, and the suggested duration of MRD. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.